Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: Non-standard dosing approaches are required to achieve therapeutic exposures

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2797-2803

  Carlier, Mieke ^a,b   Noë, Michaël ^a,b   Roberts, Jason A ^c,d   Stove, Veronique ^b   Verstraete, Alain G ^a,b   Lipman, Jeffrey ^c,d   de Waele, Jan J ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Cephalosporins; Critical care medicine; ICUs; PK PD; lactams

Indexed keywords

CEFUROXIME; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPARTMENT MODEL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PHARMACODYNAMICS; SIMULATION; BACTERIAL INFECTIONS; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG MONITORING; INTENSIVE CARE UNIT; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEFUROXIME; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES;

EID: 84929940893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku195     Document Type: Article

References (24)

1. Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011; 55: 4619-30.
2. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
3. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
4. Ulldemolins M, Roberts JA, Wallis SC et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771-8.
5. Carlier M, Noë M, De Waele JJ et al. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother 2013; 68: 2600-8.
6. Carlier M, Carrette S, Roberts J et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013; 17: R84.
7. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63.
8. Roberts JA, Kirkpatrick CM, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
9. Lipman J,Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-61.
10. Conil JM, Georges B, LavitMet al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007; 64: 27-35.
11. Nicasio AM, Ariano RE, Zelenitsky SA et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53: 1476-81.
12. Crandon JL, Ariano RE, Zelenitsky SA et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intens Care Med 2011; 37: 632-8.
13. Carlier M, Stove V, Roberts JA et al. Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012; 40: 416-22.
14. Norrby SR. Cephalosporins and related drugs. In: Grayson LM, ed. Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs. London: Edward Arnold, 2010; 1686.
15. Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother 1976; 9: 741-7.
16. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
17. Bundtzen RW, Toothaker RD, Nielson OS et al. Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 1981; 19: 443-9.
18. Viberg A, Lannergard A, Larsson A et al. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol 2006; 62: 297-303.
19. Taccone FS, Cotton F, Roisin S et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-31.
20. Taccone FS, Laterre PF, Dugernier T et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
21. EUCAST. Antimicrobial Wild Type Distributions of Microorganisms. http://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init (5 May 2014, date last accessed).
22. Udy AA, Varghese JM, Altukroni M et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
23. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489-95.
24. Wong G, Briscoe S, Adnan S et al. Protein binding of β-lactam antibiotics in critically ill patients: canwe successfully predict unbound concentrations? Antimicrob Agents Chemother 2013; 57: 6165-70.